Furthermore, germline RET testing is recommended even in patients who appear to have sporadic medullary thyroid carcinoma, as occult germline mutations are found in 1–7% of such cases and may modify both patient management and familial screening [40]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.